BCL2L12 is an anti-apoptotic protein that functions as a dual inhibitor of apoptosis through both cytoplasmic and nuclear mechanisms. In the cytoplasm, BCL2L12 directly inhibits effector caspases 3 and 7 1. In the nucleus, it forms a complex with the p53 tumor suppressor, reducing p53 protein stability and preventing its binding to target gene promoters (p21, DR5, Noxa, and PUMA), thereby blocking p53-mediated transcriptional responses to DNA damage 1. BCL2L12 is regulated by alternative splicing, with proper exon inclusion being critical for producing functional full-length protein; exon skipping results in truncated isoforms that undergo nonsense-mediated decay 2. The gene is highly relevant in cancer biology, showing genomic amplification and elevated expression in glioblastoma with intact p53 function 1 and serving as a target of YAP/TAZ signaling in hepatocellular carcinoma 3. BCL2L12 expression is dynamically regulated during chemotherapy-induced apoptosis, with initial upregulation followed by downregulation during cisplatin treatment 4. Multiple splice variants exist across cancer cell lines, suggesting complex post-transcriptional regulation 5.